Effects of the Addition of Nedocromil Sodium to Maintenance Bronchodilator therapy in the Management of Chronic Asthma (Part 8)

In the placebo group, when the theophylline dose was reduced and then finally stopped, there was a deterioration in symptoms despite an increased use of inhaled bronchodilator. In the nedocromil sodium group, however, patients appeared able to tolerate the reduction and withdrawal of theophylline therapy— symptom scores and inhaled bronchodilator usage were lower than baseline…

Read more

Effects of the Addition of Nedocromil Sodium to Maintenance Bronchodilator therapy in the Management of Chronic Asthma (Part 7)

Effects of the Addition of Nedocromil Sodium to Maintenance Bronchodilator rherapy in the Management of Chronic Asthma (Part 7)

Safety Unusual Symptoms: Both treatments were well tolerated. After two weeks of placebo treatment, one patient experienced nausea for one day during a three-day period of moderate taste loss. No other adverse reactions or unusual symptoms were recorded. Laboratory Data: Statistically significant treatment group differences were detected for changes from baseline for hemoglobin (p<0.01) and…

Read more

Effects of the Addition of Nedocromil Sodium to Maintenance Bronchodilator therapy in the Management of Chronic Asthma (Part 6)

Asthma Severity: Baseline clinic assessment of asthma severity (mild to moderate) was very similar between the two treatment groups (Table 2). Asthma severity did not differ significantly (p>0.05) between the treatment groups at the week 4, 5, or 6 assessmerits, although there was a trend toward a decrease in severity in nedocromil sodium-treated patients and…

Read more

Effects of the Addition of Nedocromil Sodium to Maintenance Bronchodilator therapy in the Management of Chronic Asthma (Part 4)

figure-1

Safety Variables Blood and urine samples for routine laboratory monitoring were taken at the time of admission into the study and on completion of the trial. At each clinic visit, the clinician recorded any unusual symptoms or adverse events. Analysis Comparisons were made on changes from baseline to reduce the between-patient variability. Two-tailed tests were…

Read more

Effects of the Addition of Nedocromil Sodium to Maintenance Bronchodilator therapy in the Management of Chronic Asthma (Part 2)

Conclusion: Nedocromil sodium, 4 mg twice daily, conferred significant benefit when added to sustained-release theophylline therapy. The results suggest that nedocromil sodium may permit a reduction in theophylline dosage and possibly substitute for theophylline in previously dependent patients. N edocromil sodium (Tilade), a pyranoquinoline derivative, is a unique topical antiasthma agent that possesses both antiallergic…

Read more